Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Dynamic Stem Cell Therapy
WARNING LETTER
•Dynamic Stem Cell Therapy•February 11, 2026

Dynamic Stem Cell Therapy – FDA Warning Letter, Feb 11, 2026

Record Details

The FDA issued a Warning Letter to Dynamic Stem Cell Therapy on February 11, 2026, following a review of their website, which markets an umbilical cord-derived stem cell product. The agency found significant violations, primarily concerning the misbranding and unapproved status of this biological product. The company markets its product with claims for treating various conditions such as sports injuries (e.g., ligament tears, rotator cuff tears), anti-aging, knee pain, and arthritis. The FDA determined that, based on these claims, the product functions as both an unapproved new drug under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and an unlicensed biological product under the Public Health Service Act (PHS Act). Crucially, the umbilical cord-derived product fails to meet the regulatory criteria for human cell, tissue, or cellular or tissue-based products (HCT/Ps). Specifically, it is not minimally manipulated, as its processing into an injectable form significantly alters its original physical characteristics. Furthermore, it is not intended for homologous use, as treating cardiovascular disease or arthritis is not a natural function of the umbilical cord in a donor. Consequently, it requires premarket review and approval, which it lacks. The product is also misbranded because it does not bear adequate directions for use, being a prescription drug. The FDA also noted concern over the company"s marketing of exosomes without appropriate approval. Dynamic Stem Cell Therapy must respond within fifteen working days, outlining concrete steps to correct these violations and prevent their recurrence, ensuring full compliance with federal regulations.

Company
Dynamic Stem Cell Therapy
Inspection date
February 11, 2026
Product type
biologics
Office
Office of Compliance and Biologics Quality
People
  • Melissa J. Mendoza (Director)
  • Dale Carrison
View Company Profile

ID · 6a69799e-4599-4779-919f-8f0041dbdd12

Violation Codes10
21 CFR 127121 CFR 1271.10(a)(2)21 U.S.C. 331(k)FD&C Act 503(b)(1)(A)21 CFR 1271.3(f)(1)21 CFR 1271.10(a)(1)FD&C Act 201(g)(1)21 CFR 1271.10(a)21 CFR 1271.1521 U.S.C. 352(f)(1)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Dynamic Stem Cell Therapy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.